BPC-157 lab monitoring
Which blood work to run before, during and after a BPC-157 cycle, and what the research can and can't tell you about the results. Only three small human studies of BPC-157 exist (26 people in total), and only one checked blood work, in two people over three days, so this panel is a safety check built from animal and pharmacokinetic data. It doesn't prove the peptide is working.
When to test
1. Baseline (before you start)
| Marker | Why test it | Standard range |
|---|---|---|
| ALT Alanine aminotransferase | BPC-157 is excreted in urine and bile, and the liver held the second-highest tissue concentration in rats (PMID 36588717). Animal studies show it protecting the liver, not harming it: ALT and AST fell in CCl4, Budd-Chiari and radiation liver-injury models (PMID 7901724, PMID 32226643, PMID 36228773). No human liver injury has been reported, and the only human blood-work data is a two-person, three-day IV pilot (PMID 40131143), so your own baseline is the reference point. | 0-45 IU/L Tighter target: 29-33 men, 19-25 women (ACG 2017 healthy upper limit) Source: Cleveland Clinic |
| AST Aspartate aminotransferase | Read alongside ALT. AST is also found in muscle, so a hard training session in the days before the draw can raise it on its own. Same liver rationale as ALT (PMID 7901724, PMID 32226643). | 0-35 IU/L Source: Cleveland Clinic |
| Creatinine Serum creatinine | BPC-157 is excreted in urine and bile, and in rats the kidney held the highest tissue concentration of any organ an hour after dosing (PMID 36588717). No kidney toxicity has been reported. | 0.76-1.27 men, 0.57-1.00 women mg/dL Source: Labcorp |
| eGFR Estimated glomerular filtration rate | Calculated from creatinine; it shows how well your kidneys filter. It is the clearance check the pharmacokinetic data points to (PMID 36588717). | Above 90 mL/min/1.73m² Source: UK Kidney Association |
| hs-CRP High-sensitivity C-reactive protein | A general inflammation baseline. BPC-157 lowered IL-6, a main driver of CRP, in a rat ischemia-reperfusion model (PMID 42204242), but no BPC-157 study has ever measured CRP itself. | Under 1.00 low risk, 1.00-3.00 average, over 3.00 high mg/L Source: Labcorp |
| ESR Erythrocyte sedimentation rate | A second, slower-moving inflammation marker to pair with hs-CRP. No BPC-157 study has measured ESR. | Men 0-15 (under 50), 0-30 (50+); women 0-32 (under 50), 0-40 (50+) mm/hour Source: Labcorp |
| CBC Complete blood count | A standard safety baseline before any injectable. FDA's compounding safety review flagged immunogenicity risk and peptide impurities for BPC-157. No BPC-157 study has reported CBC changes. | WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL Source: Cleveland Clinic |
2. Mid-cycle (week 4)
tracking only, no expected direction
| Marker | Why test it |
|---|---|
| hs-CRP High-sensitivity C-reactive protein | Tracks inflammation against your baseline. Most useful if your baseline was raised. |
| ESR Erythrocyte sedimentation rate | Paired with hs-CRP. A sharp rise during a cycle is worth a clinician's look. |
3. Post-cycle (2-4 weeks after your last dose)
| Marker | Why test it |
|---|---|
| ALT Alanine aminotransferase | Confirms liver enzymes stayed in range across the cycle. |
| AST Aspartate aminotransferase | Read with ALT; skip hard training for a couple of days before the draw. |
| Creatinine Serum creatinine | Confirms kidney clearance markers stayed in range. |
| eGFR Estimated glomerular filtration rate | Read with creatinine. |
| hs-CRP High-sensitivity C-reactive protein | Compare with baseline and week 4. |
| ESR Erythrocyte sedimentation rate | Compare with baseline and week 4. |
Ranges differ between labs, and by sex and age. Labcorp publishes its creatinine, ESR and hs-CRP ranges but not its AST, ALT or CBC ranges, so those come from Cleveland Clinic. Your own report's printed range is the one to read against.
What to expect
-
ALT and AST: expected to stay in range (baseline to post-cycle)
No human data. In rats and mice BPC-157 lowered ALT and AST after liver injury rather than raising them (PMID 7901724, PMID 32226643, PMID 36228773), and no human liver injury has been reported.
If it doesn't: A rise above range is not something the research predicts. Stop, retest, and look at what else is in the picture: other compounds in a stack, alcohol, medications, recent hard training (AST), or a contaminated or mislabeled vial.
-
Creatinine and eGFR: expected to stay in range (baseline to post-cycle)
No kidney toxicity reported in animal studies. BPC-157 is excreted in urine and bile and concentrates in the kidney in rats (PMID 36588717).
If it doesn't: A drop in eGFR or rise in creatinine is not predicted by the research. Stop and retest with a clinician.
-
hs-CRP and ESR: no established change (baseline, week 4, post-cycle)
No BPC-157 study, animal or human, has measured CRP or ESR. The closest data is IL-6 falling in a rat ischemia-reperfusion model (PMID 42204242), so a drop is possible but not shown. If your baseline is normal, expect it to stay normal.
If it doesn't: A flat CRP does not mean your BPC-157 is fake, and a falling one doesn't prove it's real. Inflammation markers move for many reasons (training, illness, sleep, diet). A clear rise is worth a clinician's look.
Your labs can't check your vial
No blood test can confirm what's in your vial. FDA's compounding safety review says BPC-157 has complexities with peptide-related impurities and characterizing the active ingredient. When independent labs tested grey-market semaglutide bought online, purity came back at 7.7-14% and every sample contained endotoxin (PMID 39509151). That study was on semaglutide, not BPC-157. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.
What the research doesn't show
- Only three human BPC-157 studies are published (PMID 34324435, PMID 39325560, PMID 40131143), 26 people in total. Only the two-person IV pilot reports checking blood work at all.
- That IV pilot (10 mg then 20 mg over two days) reported no measurable effects on heart, liver, kidney, thyroid or blood-glucose markers (PMID 40131143). Two people over three days says little about a multi-week cycle.
- CRP and ESR have never been measured in a BPC-157 study.
- BPC-157 activates VEGFR2, the receptor for VEGF, a growth signal for new blood vessels (PMID 40789979). No lab test covers that. If you have a cancer history, talk to your oncologist before using it.
Sources
- Cleveland Clinic: Liver function tests (ALT, AST normal ranges)
- Kwo PY, et al. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017. PMID 27995906
- Labcorp test 001370: Creatinine (reference range)
- UK Kidney Association: CKD staging (eGFR)
- Labcorp test 120766: C-reactive protein, high sensitivity (cardiac risk tiers)
- Pearson TA, et al. Markers of inflammation and cardiovascular disease (AHA/CDC). Circulation 2003. PMID 12551878
- Labcorp test 005215: Sedimentation rate, erythrocyte (reference range)
- Cleveland Clinic: Complete blood count (normal values for adults)
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC 157 in rats and dogs. Front Pharmacol 2022. PMID 36588717
- Sikiric P, et al. Hepatoprotective effect of BPC 157 on liver lesions in rats. Life Sci 1993. PMID 7901724
- Gojkovic S, et al. BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. 2020. PMID 32226643
- Huang BS, et al. BPC 157 reduces radiation-induced liver injury through Kruppel-like factor 4 upregulation. Life Sci 2022. PMID 36228773
- Yildirim AK, et al. Protective effects of BPC 157 in rats with lower extremity ischemia-reperfusion injury. Sci Rep 2026. PMID 42204242
- Lee E, et al. Intra-articular injection of BPC 157 for multiple types of knee pain. 2021. PMID 34324435
- Lee E, et al. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. 2024. PMID 39325560
- Lee E, et al. Safety of intravenous infusion of BPC157 in humans: a pilot study. 2025. PMID 40131143
- Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res 2024. PMID 39509151
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (BPC-157)
Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.